HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study
PLoS Medicine Oct 21, 2021
Bergqvist R, Ahlqvist VH, Lundberg M, et al. - Lipid-lowering HMG-CoA reductase inhibitors (statins) are reported to have pleiotropic effects on coagulation and immune mechanisms. Considering this, researchers herein examined the correlation of statin treatment with COVID-19 mortality.
Swedish health registers yielded data of a cohort of 963,876 residents of Stockholm, Sweden.
Follow-up of the cohort was done from March 1, 2020 until November 11, 2020.
Researchers matched prescription dispensation data to healthcare data and the Swedish Cause of Death Registry.
Multivariable cause-specific survival analysis was conducted to analyze the data.
After accounting for a series of preexisting health conditions and other factors, there appeared a moderately lower risk of COVID-19 mortality in correlation with receiving statin treatment.
Sensitivity analyses corroborated the association and no substantial variation in this association was recorded across risk groups.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries